The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Open accessAbstract
The echinocandin MK-0991, formerly L-743,872, is a water-soluble lipopeptide that has been demonstrated in preclinical studies to have potent activity against Candida spp., Aspergillus fumigatus, and Pneumocystis carinii. An extensive in vitro biological evaluation of MK-0991 was performed to better define the potential activities of this novel compound. Susceptibility testing with MK-0991 against approximately 200 clinical isolates of Candida, Cryptococcus neoformans, and Aspergillus isolates was conducted to determine MICs and minimum fungicidal concentrations MF(s). The MFC at which 90% of isolates are inhibited for 40 C. albicans clinical isolates was 0.5 microg/ml. Susceptibility testing with panels of antifungal agent-resistant species of Candida and C. neoformans isolates indicated that the MK-0991 MFCs for these isolates are comparable to those obtained for susceptible isolates. Growth kinetic studies of MK-0991 against Candida albicans and Candida tropicalis isolates showed that the compound exhibited fungicidal activity (i.e., a 99% reduction in viability) within 3 to 7 h at concentrations ranging from 0.06 to 1 microg/ml (0.25 to 4 times the MIC). Drug combination studies with MK-0991 plus amphotericin B found that this combination was not antagonistic against C. albicans, C. neoformans, or A. fumigatus in vitro. Studies with 0 to 50% pooled human or mouse serum established that fungal susceptibility to MK-0991 was not significantly influenced by the presence of human or mouse serum. Results from resistance induction studies suggested that the susceptibility of C. albicans was not altered by repeated exposure (40 passages) to MK-0991. Erythrocyte hemolysis studies with MK-0991 with washed and unwashed human or mouse erythrocytes indicated minimal hemolytic potential with this compound. These favorable results of preclinical studies support further studies with MK-0991 with humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Komshian, S. V., Uwaydah, A. K., Sobel, J. D., & Crane, L. R. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.3.379 · Cited by 457
Kurtz, M. B., Heath, I. B., Marrinan, J., Dreikorn, S., Onishi, J., & Douglas, C. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1480 · Cited by 320
New Spectrum of Fungal Infections in Patients with Cancer
Anaissie, E., Bodey, G. P., Kantarjian, H., Ro, J., Vartivarian, S. E., Hopfer, R., Hoy, J., & Rolston, K. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.3.369 · Cited by 259
Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E., & Trautmann, M. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.9.2092-2098.1994 · Cited by 251
Fluconazole resistance in Candida glabrata
Hitchcock, C. A., Pye, G. W., Troke, P. F., Johnson, E. M., & Warnock, D. W. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1962 · Cited by 244
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests
Espinel-Ingroff, A., Kish, C. W., Kerkering, T. M., Fromtling, R. A., Bartizal, K., Galgiani, J. N., Villareal, K., Pfaller, M. A., Gerarden, T., & Rinaldi, M. G. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.12.3138-3145.1992 · Cited by 243
Self-citationCompounds active against cell walls of medically important fungi
Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242
Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L., Smith, J. G., Pikounis, V. B., Balkovec, J. M., Bouffard, A. F., Dropinski, J. F., Rosen, H., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2333 · Cited by 241
Self-citationHospital-acquired infections: diseases with increasingly limited therapies.
Swartz, M. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2420 · Cited by 232
Cited by
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszynska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 919
Candida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Candida biofilms on implanted biomaterials: a clinically significant problem
Ramage, G., MartÃnez, J. P., & López-Ribot, J. L. (2006) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00117.x · Cited by 575
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Self-citationSanglard, D., Ischer, F., Marchetti, O., Entenza, J., & Bille, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03495.x · Cited by 350
“Even though caspofungin, an inhibitor of b-1,3 glucan synthase, was reported to possess some intrinsic fungicidal activity in C. albicans (Bartizal et al., 1997), the incubation of DSY2091 at a drug concentration above the MIC value resulted in an enhanced killing activity compared with the wild…”
BackgroundFungal ß(1,3)-D-glucan synthesis
Douglas, C. M. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.55.66 · Cited by 312
Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.57-62.2000 · Cited by 311
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303
“At concentrations of AMB that significantly reduce the number of CFU, the level of fluorescent staining with the dye 5,(6)-carboxyfluorescein diacetate (CFDA), which stains live cells, decreased, while the level of staining with the dye bis(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC), which stains dead cells…”
BackgroundMethodResultEchinocandins: a new class of antifungal
Denning, D. W. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf045 · Cited by 300
Saravolatz, L. D., Deresinski, S. C., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/375080 · Cited by 293
In Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Kirkpatrick, W. R., Perea, S., Coco, B. J., & Patterson, T. F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2564-2568.2002 · Cited by 282
(2003) · PubMed · Cited by 240
Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-12 · Cited by 214
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
Thompson, J. R., Douglas, C. M., Li, W., Jue, C. K., Pramanik, B., Yuan, X., Rude, T. H., Toffaletti, D. L., Perfect, J. R., & Kurtz, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.2.444-453.1999 · Cited by 196
Ernst, E. J., Klepser, M. E., & Pfaller, M. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1108-1111.2000 · Cited by 181
“The activity of these agents has been described as either fungicidal or fungistatic, depending on the isolate and test conditions (1, 3).”
BackgroundMaligie, M. A., & Selitrennikoff, C. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2851-2856.2005 · Cited by 178
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
Wiederhold, N. P., & Lewis, R. E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1313 · Cited by 144
Echinocandins: the expanding antifungal armamentarium
Aguilar-Zapata, D., Petraitiene, R., & Petraitis, V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ814 · Cited by 112
Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis
Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., & Scalise, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-06 · Cited by 98
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85
Clancy, C. J., Huang, H., Cheng, S., Derendorf, H., & Nguyen, M. H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-06 · Cited by 73
New Methods To Assess Susceptibilities of Aspergillus Isolates to Caspofungin
Imhof, A., Balajee, S. A., & Marr, K. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5683-5688.2003 · Cited by 48
Pianalto, K. M., Billmyre, R. B., Telzrow, C. L., & Alspaugh, J. A. (2019) · Genetics · doi:10.1534/genetics.119.302290 · Cited by 41
Killing Kinetics of Caspofungin, Micafungin, and Amphotericin B against Candida guilliermondii
Cantón, E., Pemán, J., Sastre, M., Romero, M., & Espinel-Ingroff, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00524-06 · Cited by 37
Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.
Desnos-Ollivier, M., Moquet, O., Chouaki, T., Guérin, A.-M., & Dromer, F. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00325-11 · Cited by 37
Aspergillus fumigatus and Aspergillosis
(2008) · doi:10.1128/9781555815523 · Cited by 31
Metadata
- Authors
- Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., & Balkovec, J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-11
- Volume
- 41
- Issue
- 11
- Pages
- 2326-2332
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2124458223
- Cited by
- 311
- References
- 21
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.